BiotechTube

INCB054707 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NonSegmental Vitiligo

Conditions

NonSegmental Vitiligo

Trial Timeline

May 6, 2021 → May 24, 2023

NCT ID
NCT04818346

About INCB054707 + Placebo

INCB054707 + Placebo is a phase 2 stage product being developed by Incyte for NonSegmental Vitiligo. The current trial status is completed. This product is registered under clinical trial identifier NCT04818346. Target conditions include NonSegmental Vitiligo.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT05061693Phase 2Completed
NCT05068466Phase 1Completed
NCT04818346Phase 2Completed
NCT04476043Phase 2Completed
NCT03607487Phase 2Completed

Competing Products

7 competing products in NonSegmental Vitiligo

See all competitors
ProductCompanyStageHype Score
Ritlecitinib + Ritlecitinib + PlaceboPfizerPhase 3
76
Ritlecitinib + PlaceboPfizerPhase 3
76
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
Ruxolitinib CreamIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Povorcitinib + PlaceboIncytePhase 3
74

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74